218 related articles for article (PubMed ID: 34238066)
1. NT157 Inhibits HCC Migration via Downregulating the STAT3/Jab1 Signaling Pathway.
Yu S; Wang Y; Lv K; Hou J; Li W; Wang X; Guo H; Wang W
Technol Cancer Res Treat; 2021; 20():15330338211027916. PubMed ID: 34238066
[TBL] [Abstract][Full Text] [Related]
2. Stat3 and CCAAT/enhancer binding protein beta (C/EBP-beta) regulate Jab1/CSN5 expression in mammary carcinoma cells.
Shackleford TJ; Zhang Q; Tian L; Vu TT; Korapati AL; Baumgartner AM; Le XF; Liao WS; Claret FX
Breast Cancer Res; 2011 Jun; 13(3):R65. PubMed ID: 21689417
[TBL] [Abstract][Full Text] [Related]
3. Stat3 contributes to cancer progression by regulating Jab1/Csn5 expression.
Pan Y; Wang S; Su B; Zhou F; Zhang R; Xu T; Zhang R; Leventaki V; Drakos E; Liu W; Claret FX
Oncogene; 2017 Feb; 36(8):1069-1079. PubMed ID: 27524414
[TBL] [Abstract][Full Text] [Related]
4. Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells.
Yang Y; Chan JY; Temiz NA; Yee D
Horm Cancer; 2018 Dec; 9(6):371-382. PubMed ID: 30229539
[TBL] [Abstract][Full Text] [Related]
5. CSN5 Promotes Hepatocellular Carcinoma Progression by SCARA5 Inhibition Through Suppressing β-Catenin Ubiquitination.
Liu H; Hu J; Pan H; Luo D; Huang M; Xu W
Dig Dis Sci; 2018 Jan; 63(1):155-165. PubMed ID: 29189991
[TBL] [Abstract][Full Text] [Related]
6. Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer.
Nam AR; Kim JW; Park JE; Bang JH; Jin MH; Oh DY; Bang YJ
Cancer Res Treat; 2019 Jul; 51(3):886-900. PubMed ID: 30282449
[TBL] [Abstract][Full Text] [Related]
7. Rheum palmatum extract exerts anti-hepatocellular carcinoma effects by inhibiting signal transducer and activator of transcription 3 signaling.
Tan ZB; Fan HJ; Wu YT; Xie LP; Bi YM; Xu HL; Chen HM; Li J; Liu B; Zhou YC
J Ethnopharmacol; 2019 Mar; 232():62-72. PubMed ID: 30553869
[TBL] [Abstract][Full Text] [Related]
8. Ascochlorin, an isoprenoid antibiotic inhibits growth and invasion of hepatocellular carcinoma by targeting STAT3 signaling cascade through the induction of PIAS3.
Dai X; Ahn KS; Kim C; Siveen KS; Ong TH; Shanmugam MK; Li F; Shi J; Kumar AP; Wang LZ; Goh BC; Magae J; Hui KM; Sethi G
Mol Oncol; 2015 Apr; 9(4):818-33. PubMed ID: 25624051
[TBL] [Abstract][Full Text] [Related]
9. Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling.
Flashner-Abramson E; Klein S; Mullin G; Shoshan E; Song R; Shir A; Langut Y; Bar-Eli M; Reuveni H; Levitzki A
Oncogene; 2016 May; 35(20):2675-80. PubMed ID: 26119932
[TBL] [Abstract][Full Text] [Related]
10. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2
Fenerich BA; Fernandes JC; Rodrigues Alves APN; Coelho-Silva JL; Scopim-Ribeiro R; Scheucher PS; Eide CA; Tognon CE; Druker BJ; Rego EM; Machado-Neto JA; Traina F
Signal Transduct Target Ther; 2020 Jan; 5(1):5. PubMed ID: 32296029
[TBL] [Abstract][Full Text] [Related]
11. Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF-κB/STAT3 and NF-κB/CSN5 signaling pathways.
Ruan Z; Liang M; Shang L; Lai M; Deng X; Su X
Pancreatology; 2021 Apr; 21(3):630-641. PubMed ID: 33707115
[TBL] [Abstract][Full Text] [Related]
12. The TGFβ-induced lncRNA TBILA promotes non-small cell lung cancer progression in vitro and in vivo via cis-regulating HGAL and activating S100A7/JAB1 signaling.
Lu Z; Li Y; Che Y; Huang J; Sun S; Mao S; Lei Y; Li N; Sun N; He J
Cancer Lett; 2018 Sep; 432():156-168. PubMed ID: 29908210
[TBL] [Abstract][Full Text] [Related]
13. Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo.
Mohan CD; Bharathkumar H; Bulusu KC; Pandey V; Rangappa S; Fuchs JE; Shanmugam MK; Dai X; Li F; Deivasigamani A; Hui KM; Kumar AP; Lobie PE; Bender A; Basappa ; Sethi G; Rangappa KS
J Biol Chem; 2014 Dec; 289(49):34296-307. PubMed ID: 25320076
[TBL] [Abstract][Full Text] [Related]
14. NT157 exerts antineoplastic activity by targeting JNK and AXL signaling in lung cancer cells.
de Miranda LBL; Lima K; Coelho-Silva JL; Traina F; Kobayashi SS; Machado-Neto JA
Sci Rep; 2022 Oct; 12(1):17092. PubMed ID: 36224313
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
Gu FM; Li QL; Gao Q; Jiang JH; Huang XY; Pan JF; Fan J; Zhou J
World J Gastroenterol; 2011 Sep; 17(34):3922-32. PubMed ID: 22025881
[TBL] [Abstract][Full Text] [Related]
16. α5-nAChR contributes to epithelial-mesenchymal transition and metastasis by regulating Jab1/Csn5 signalling in lung cancer.
Chen X; Jia Y; Zhang Y; Zhou D; Sun H; Ma X
J Cell Mol Med; 2020 Feb; 24(4):2497-2506. PubMed ID: 31930655
[TBL] [Abstract][Full Text] [Related]
17. In vivo and in vitro effects of microRNA-221 on hepatocellular carcinoma development and progression through the JAK-STAT3 signaling pathway by targeting SOCS3.
Huang S; Zhou D; Li YX; Ming ZY; Li KZ; Wu GB; Chen C; Zhao YN
J Cell Physiol; 2019 Apr; 234(4):3500-3514. PubMed ID: 30370582
[TBL] [Abstract][Full Text] [Related]
18. JAB1 and phospho-Ser10 p27 expression profile determine human hepatocellular carcinoma prognosis.
Wang Y; Yu YN; Song S; Li TJ; Xiang JY; Zhang H; Lu MD; Ji F; Hu LQ
J Cancer Res Clin Oncol; 2014 Jun; 140(6):969-78. PubMed ID: 24671224
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor{gamma} ligands in vitro and in vivo.
Hsu MC; Huang CC; Chang HC; Hu TH; Hung WC
Clin Cancer Res; 2008 Jul; 14(13):4045-52. PubMed ID: 18593980
[TBL] [Abstract][Full Text] [Related]
20. CSN5 upregulates glycolysis to promote hepatocellular carcinoma metastasis via stabilizing the HK2 protein.
Huang M; Xiong H; Luo D; Xu B; Liu H
Exp Cell Res; 2020 Mar; 388(2):111876. PubMed ID: 31991125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
